Human melanoma specific immunotoxins
US4590071A · kind A · utility
51Cited by
7References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 25, 1984 |
| Grant date | May 20, 1986 |
| Priority date | — |
| Expiry date | Sep 25, 2004 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Conjugates of monoclonal antibodies specific to human melanoma and the A chain of a toxic lectin such as ricin or an equivalent ribosomal inhibiting protein. The conjugate is synthesized by a novel process employing anti-toxic lectin B chain antibodies to remove lectin B chain impurities and provide a highly purified conjugate that is non-toxic to cells other than melanoma. The conjugates are used to treat human melanoma. The hybridomas XMMME-001 and XMMME-002 were deposited with the American Type Culture Collection (A.T.C.C.) on Mar. 26, 1985, and given A.T.C.C. Accession Nos. HB8759 and HB8760, respectively.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.